Amid unrelenting chaos and violence, scientists and doctors in the Democratic Republic of Congo have been running a clinical trial of new drugs to try to combat a year-long Ebola outbreak. On Monday, the trial’s cosponsors at the World Health Organization and the National Institutes of Health announced that two of the experimental treatments appear to dramatically boost survival rates.

While an experimental vaccine previously had been shown to shield people from catching Ebola, the news marks a first for people who already have been infected. “From now on, we will no longer say that Ebola is incurable,” said Jean-Jacques Muyembe, director general of the Institut National de Recherche Biomedicale in the DRC, which has overseen the trial’s operations on the ground.

Starting last November, patients in four treatment centers in the country’s east, where the outbreak is at its worst, were randomly assigned to receive one of four investigational therapies—either an antiviral drug called remdesivir or one of three drugs that use monoclonal antibodies. Scientists concocted these big, Y-shaped proteins to recognize the specific shapes of invading bacteria and viruses and then recruit immune cells to attack those pathogens. One of these, a drug called ZMapp, is currently considered the standard of care during Ebola outbreaks. It had been tested and used during the devastating Ebola epidemic in West Africa in 2014, and the goal was to see if those other drugs could outperform it. But preliminary data from the first 681 patients (out of a planned 725) showed such strong results that the trial has now been stopped.

A widespread outbreak of Legionnaires’ disease has killed one person and sickened possibly dozens of others who were all guests at the Sheraton Atlanta Hotel. The hotel evacuated all its guests on July 15 and remains closed as of press time.

Public health officials say a dozen guests had tested positive for Legionnaires’, a bacteria that can cause a severe form of pneumonia. But according to the attorney filing a lawsuit Monday, hundreds more may have been exposed.

By the time guests were evacuated in mid-July, 49-year-old Cameo Garrett was already dead. An autopsy showed she had coronary issues and Legionnaires’ disease. Garrett went to a conference at the Sheraton a week before she died – just like Germany Greer who said he became so sick at one point he didn’t even know his own name.

Fighting Antibiotic Resistance By Repurposing Old Drugs : Shots — Health News Scientists discovered that a medication used to treat parasites in horses can fight deadly staph infections. It’s a promising new approach to solving the problem of antibiotic resistance.

Living healthier and longer can depend on probiotics more than we ever thought.

---

The bacteria in our gut make thousands of tiny, previously unidentified proteins that could shed light on human health and advance drug development, Stanford researchers have found.

Prior studies in mice have shown that whole body vibration (WBV) can mimic some of the positive effects on health of exercise, and even reverse some of the symptoms of type 2 diabetes. New research by a team at the Medical College of Georgia (MCG) and Dental College of Georgia (DCG) at Augusta University has provided new clues as to the mechanisms involved. Their studies in a mouse model of obesity showed that WBV results in increased levels of inflammation-suppressing immune system macrophages, and high numbers of gut bacteria that makes short-chain fatty acids (SCFAs), which can help the body better utilize glucose.

The findings “… support the notion that WBV has the potential to alter the microbiota in a way that triggers innate and mucosal immunity to produce anti-inflammatory responses, down-regulating the hyper-inflammatory state and reversing the adverse consequences,” the investigators wrote in their published paper in the International Journal of Molecular Sciences. “More studies are required to solidify this novel approach, which can be a very affordable and effective therapeutic modality in the prevention and treatment of many diseases, including diabetes and obesity.” The researchers, headed by Jack Yu, MD, chief of pediatric plastic surgery at MCG, and Babak Baban, PhD, immunologist and intern associate dean for research at DCG, reported their findings in a paper titled, “Whole Body Vibration-Induced Omental Macrophage Polarization and Fecal Microbiome Modification in a Murine Model.”

The combination of high-fat, sugar-heavy diets and “massively reduced physical activities” is largely responsible for what the researchers called “an epidemic of obesity and chronic metabolic diseases,” including type 2 diabetes. Chronic inflammation is a major contributory factor to the development of metabolic and cardiovascular diseases, and the immune system’s macrophages play a key role in regulating inflammatory responses.